Overview

Dose-finding Study of ASP2151 in Subjects With Herpes Zoster

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of three different doses of ASP2151, as compared to valacyclovir hydrochloride in subjects with herpes zoster, and to determine the recommended clinical dose.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Acyclovir
Valacyclovir